SPX 101

Drug Profile

SPX 101

Alternative Names: SPX-101

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spyryx Biosciences
  • Class Peptides
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 02 Aug 2017 Spyryx Biosciences completes a phase Ib trial in Cystic fibrosis in Canada (Inhalation) (NCT03056989)
  • 01 Aug 2017 Phase-II clinical trials in Cystic fibrosis in Portugal, Canada (Inhalation) (EudraCT2016-005230-30) (NCT03229252)
  • 20 Jun 2017 Efficacy data from a phase I trial in Cystic fibrosis released by Spyryx Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top